Power Law company profile

Cogent Biosciences

Biotech & Life Sciences · Cambridge, United States · Founded 2014 · IPO 2018 Unicorn

Developing precision therapies for genetically defined diseases

Valuation

$5.54B

Market cap · May/2026

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

18 investors on Cogent Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 18 investors entered at this stage

Commodore Capital

F-Prime

TCGX

Cowen Group

Janus Health Technologies

Perceptive Advisors

Novo Seeds

Fairmount Funds Management

Adage Capital

Venrock

Redmile Group

Deerfield

Sanofi Ventures

Seagen

Jennison Associates

Wellington Management

Sectoral Asset Management

New Leaf Venture Partners

Global footprint

Where Cogent Biosciences has talent and traffic

Workforce by country

🇺🇸 United States · Cambridge HQ

Book a demo for the full country breakdown

Web traffic by country

17K monthly visits
across markets

🇺🇸 United States47.1%

🇮🇳 India15.3%

🇫🇷 France10%

🇨🇦 Canada8.2%

🇯🇵 Japan7.1%

Top 5 markets shown

Market sentiment

What the market is saying about Cogent Biosciences

An AI-synthesized read of the highest-engagement posts about Cogent Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cogent Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles